Postpartum Smoking Relapse Clinical Trial
Official title:
Bupropion for the Prevention of Postpartum Smoking Relapse
This two-arm, double-blind, placebo-controlled randomized clinical trial will enroll pregnant women who quit smoking after learning they were pregnant and are motivated to stay abstinent postpartum. Participants will be randomized to receive extended-release bupropion (active 300mg or placebo once daily beginning 4 to 10 days postpartum to 12 weeks post-randomization). All participants will complete the same data collection procedures (e.g., biological sample collection for hormone and cotinine analysis and completion of validated questionnaires) at baseline (gestational week 36), weekly from 4 to 10 days postpartum through 12 weeks post-randomization and at weeks 12, 24, 36 and 52 post-randomization.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04114877 -
Perinatal Attentional Retraining Intervention for Smoking for Minority Women
|
N/A | |
| Completed |
NCT05711225 -
Transtheoretic Model, Postpartum Smoking Relapse, Smoking Cessation Intervention
|
N/A |